Answer
Cemiplimab (Libtayo) is indicated as monotherapy for adults with recurrent or metastatic cervical cancer whose disease has progressed on or after platinum-based chemotherapy.
Sources for this answer
- LIBTAYO 350 mg concentrate for solution for infusion.Regeneron UK Limited · emc · SmPC §4.1 Therapeutic Indications · Version 24Document updated
Sources checked